Intranasal Ketamine
ApprovedSmall molecule
Intranasal Ketamine is one of 262 small molecule programs targeting Abscess. It is currently in Approved.
9
Indications
29
Total Trials
5
Active Trials
261
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Intranasal Ketamine
JJavelin Pharmaceuticals
Approved
Bupropion XL
GSKPhase 3
ALKS 37
AAlkermes, Inc.
Phase 3
Desvenlafaxine SR
PfizerPhase 3
SPD489
TakedaPhase 3
Brenipatide
Eli LillyPhase 3
Venlafaxine ER
PfizerPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
MK0869, Aprepitant
Merck & Co.Phase 3
TC-5214
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sedation4 trials
Children2 trials
Randomized Controlled Trial1 trial
20 more indications
Buprenorphine1 trial
Safety and Efficacy1 trial
Major Depressive Disorder1 trial
Nerve Block1 trial
Alcohol Abuse1 trial
Dexmedetomidine1 trial
Depressive Disorder1 trial
Treatment Resistant Depression1 trial
Drug Interactions1 trial
Pilot Study1 trial
Sickle Cell Disease1 trial
Unspecified1 trial
INK Feasibility Study
Withdrawn·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT05783492
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intranasal Ketamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- JJavelin Pharmaceuticals